Wet AMD Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Wet Age-related Macular Degeneration is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Anti-VEGF Therapies, and Growing Preference for Long-acting and Gene-based Treatment Approaches. Additionally, the launch of emerging therapies such as Ixoberogene soroparvovec (Adverum Biotechnologies), RGX-314 (Regenxbio/AbbVie), OGX-110 (Ocugenix), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Wet Age-related Macular Degeneration, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Wet AMD Market
• The market size for Wet Age-related Macular Degeneration in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Wet Age-related Macular Degeneration treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• Data from epidemiological studies indicate that in 2025, the total prevalent cases of AMD were nearly 72 million in the 7MM, reflecting the growing burden of the disease.
• Leading Wet Age-related Macular Degeneration companies, such as Roche, Novartis, Alkahest, Regenxbio, 4D Molecular Therapeutics, Outlook Therapeutics, Adverum Biotechnologies, Ocugenix, and others, are developing new Wet Age-related Macular Degeneration treatment drugs that can be available in the Wet Age-related Macular Degeneration market in the coming years.
• The promising Wet Age-related Macular Degeneration therapies in clinical trials include Ixoberogene soroparvovec, RGX-314, AKST4290, 4D-150, OGX-110, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Wet AMD Market
Rising Disease Prevalence and Diagnosis Rates: Increasing prevalence of Wet Age-related Macular Degeneration, improved screening tools, and expanding healthcare access are helping identify more patients. Earlier diagnosis and better recognition are contributing to treatment demand.
Increasing Demand for Effective Pharmacological Therapies: The pharmacological treatment of Wet Age-related Macular Degeneration primarily involves anti-VEGF agents such as aflibercept, ranibizumab, brolucizumab, and faricimab. These therapies help prevent vision loss and improve clinical outcomes.
Growing Preference for Personalized and Non-drug Therapies: Gene therapies and sustained-delivery approaches are increasingly utilized to reduce treatment burden. These approaches aim to provide long-term disease control and reduce the frequency of intravitreal injections.

Wet AMD Market Analysis
• Intravitreal anti-VEGF therapy remains the primary treatment approach for wet age-related macular degeneration. These therapies are effective in preventing vision loss and, in certain cases, can even lead to visual improvement.
• Approved treatment options for wet-AMD encompass several agents, including aflibercept (EYLEA), ranibizumab (LUCENTIS), brolucizumab (BEOVU), and faricimab (VABYSMO).
• Additionally, biosimilar versions of ranibizumab and aflibercept are also available in the market. In the United States, retina specialists frequently rely on repackaged bevacizumab (LYTENAVA) as an off-label option.
• Notably, bevacizumab became the first and only ophthalmic formulation approved for wet-AMD treatment in the European Union and the United Kingdom on May 28, 2024.
• The pipeline for wet-AMD therapies is also evolving, with promising candidates such as Ixoberogene soroparvovec (Ixo-vec) (Adverum Biotechnologies), Surabgene lomparvovec (RGX-314) (Regenxbio/AbbVie), OGX-110 (Ocugenix), AKST4290 (Alkahest), RBM-007 (Ribomic USA), 4D 150 (4D Molecular Therapeutics), AM712 (AffaMed Therapeutics), CLS-AX (axitinib) (Clearside Biomedical), CG-P5 peptide (Caregen), NG101 (Elisigen), NT-101 (NexThera), Migaldendranib (MGB) (Ashvattha Therapeutics), ABI-110 (Avirmax Biopharma), and others currently under investigation.
• Overall, the wet-AMD treatment landscape is expected to undergo substantial transformation between 2026 and 2036.
Wet AMD Competitive Landscape
• Several Wet Age-related Macular Degeneration drugs in development include Ixoberogene soroparvovec (Ixo-vec) (Adverum Biotechnologies), Surabgene lomparvovec (RGX-314) (Regenxbio/AbbVie), OGX-110 (Ocugenix), AKST4290 (Alkahest), RBM-007 (Ribomic USA), 4D 150 (4D Molecular Therapeutics), AM712 (AffaMed Therapeutics), CLS-AX (axitinib) (Clearside Biomedical), CG-P5 peptide (Caregen), NG101 (Elisigen), NT-101 (NexThera), Migaldendranib (MGB) (Ashvattha Therapeutics), ABI-110 (Avirmax Biopharma), and others.
• These candidates target diverse mechanisms such as gene therapy-based anti-VEGF delivery, inhibition of abnormal blood vessel formation, and fibrosis modulation, aiming to improve visual outcomes with better efficacy and reduced treatment burden than current therapies.

Discover more about therapies set to grab major Wet Age-related Macular Degeneration market share at: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Wet AMD Market
• In March 2026, Outlook Therapeutics provided an update following its recent Type A meeting with the US Food and Drug Administration (FDA) to discuss Complete Response Letter (CRL) for bevacizumab (LYTENAVA) for treatment of Wet Age-related Macular Degeneration.
• In October 2025, Regenxbio announced the completion of Phase II pivotal trials evaluating surabgene lomparvovec (RGX-314) for the treatment of Wet Age-related Macular Degeneration, with topline data expected in 2026.
• In December 2025, Outlook Therapeutics announced that the US FDA issued CRL declining to approve bevacizumab (LYTENAVA) for the treatment of Wet Age-related Macular Degeneration.

What is Wet AMD?
Wet Age-related Macular Degeneration, also known as neovascular AMD, causes abnormal blood vessel growth under the retina, leading to leakage, scarring, and rapid vision loss. These changes significantly impact daily functioning and visual acuity. It accounts for approximately 10% of AMD cases but nearly 90% of AMD-related central vision loss.

Wet AMD Epidemiology Segmentation
The Wet Age-related Macular Degeneration epidemiology section provides insights into the historical and current Wet Age-related Macular Degeneration patient pool and forecasted trends for the leading markets. The Wet Age-related Macular Degeneration market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
• Total Diagnosed Prevalent Cases of Wet Age-related Macular Degeneration
• Type-specific Diagnosed Prevalent Cases of Wet Age-related Macular Degeneration
• Stage-specific Diagnosed Prevalent Cases of Wet Age-related Macular Degeneration
• Age-specific Diagnosed Prevalent Cases of Wet Age-related Macular Degeneration

Scope of the Wet AMD Market Report
• Therapeutic Assessment: Wet Age-related Macular Degeneration current marketed and emerging therapies
• Wet Age-related Macular Degeneration Market Dynamics: Key Market Forecast Assumptions of Emerging Wet Age-related Macular Degeneration Drugs and Market Outlook
• Key Companies: Roche, Novartis, Alkahest, Regenxbio, Adverum Biotechnologies, Ocugenix, and others
• Key Therapies: EYLEA, LUCENTIS, BEOVU, VABYSMO, Ixoberogene soroparvovec, RGX-314, OGX-110, and others
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Wet Age-related Macular Degeneration Market Access and Reimbursement

To know more about Wet Age-related companies working in the treatment market, visit at: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Wet Age-related Macular Degeneration Market Report Introduction
2. Executive Summary for Wet Age-related Macular Degeneration
3. SWOT Analysis of Wet Age-related Macular Degeneration
4. Wet Age-related Macular Degeneration Patient Share (%) Overview at a Glance
5. Wet Age-related Macular Degeneration Market Overview at a Glance
6. Wet Age-related Macular Degeneration Background and Overview
7. Wet Age-related Macular Degeneration Epidemiology and Patient Population
8. Country-Specific Patient Population of Wet Age-related Macular Degeneration
9. Wet Age-related Macular Degeneration Current Treatment and Medical Practices
10. Wet Age-related Macular Degeneration Unmet Needs
11. Wet Age-related Macular Degeneration Emerging Therapies
12. Wet Age-related Macular Degeneration Market Outlook
13. Country-Wise Wet Age-related Macular Degeneration Market Analysis (2022-2036)
14. Wet Age-related Macular Degeneration Market Access and Reimbursement of Therapies
15. Wet Age-related Macular Degeneration Market Drivers
16. Wet Age-related Macular Degeneration Market Barriers
17. Wet Age-related Macular Degeneration Appendix
18. Wet Age-related Macular Degeneration Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.